Cetuximab Outperforms Durvalumab in Treatment of Head and Neck Cancers
University of California San DiegoThe standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune checkpoint inhibitor.